Insider Transactions in Q1 2021 at Adaptive Biotechnologies Corp (ADPT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 08
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.29%
|
$610,000
$61.8 P/Share
|
|
Feb 05
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-67.17%
|
$885,000
$59.88 P/Share
|
|
Feb 05
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 04
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-77.68%
|
$885,000
$59.01 P/Share
|
|
Feb 04
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 03
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-68.85%
|
$459,610
$59.92 P/Share
|
|
Feb 03
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+47.91%
|
$46,740
$6.32 P/Share
|
|
Feb 03
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-81.12%
|
$900,000
$60.12 P/Share
|
|
Feb 03
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 02
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-52.38%
|
$459,610
$59.71 P/Share
|
|
Feb 02
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+47.91%
|
$46,740
$6.32 P/Share
|
|
Feb 02
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-74.61%
|
$885,000
$59.26 P/Share
|
|
Feb 02
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Feb 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
6,770
-97.78%
|
$379,120
$56.01 P/Share
|
|
Feb 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
6,770
+34.03%
|
$40,620
$6.79 P/Share
|
|
Feb 01
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,790
-66.84%
|
$428,450
$55.86 P/Share
|
|
Feb 01
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,790
+47.91%
|
$46,740
$6.32 P/Share
|
|
Feb 01
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-86.48%
|
$825,000
$55.68 P/Share
|
|
Feb 01
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 29
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-76.17%
|
$840,000
$56.7 P/Share
|
|
Jan 29
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 29
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,813
-31.77%
|
$157,528
$56.69 P/Share
|
|
Jan 29
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+30.45%
|
$19,691
$7.18 P/Share
|
|
Jan 29
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-72.87%
|
$2,800,000
$56.72 P/Share
|
|
Jan 29
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 28
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-54.99%
|
$2,800,000
$56.01 P/Share
|
|
Jan 28
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 28
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-68.65%
|
$825,000
$55.87 P/Share
|
|
Jan 28
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 28
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.14%
|
$560,000
$56.53 P/Share
|
|
Jan 27
2021
|
Lance Baldo Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
40,000
-69.0%
|
$2,360,000
$59.16 P/Share
|
|
Jan 27
2021
|
Lance Baldo Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$280,000
$7.8 P/Share
|
|
Jan 27
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-74.28%
|
$885,000
$59.18 P/Share
|
|
Jan 27
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 27
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.11%
|
$570,000
$57.42 P/Share
|
|
Jan 26
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
10,000
-0.14%
|
$630,000
$63.97 P/Share
|
|
Jan 26
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-86.04%
|
$975,000
$65.17 P/Share
|
|
Jan 26
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 26
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-53.18%
|
$3,200,000
$64.09 P/Share
|
|
Jan 26
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 25
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-59.18%
|
$990,000
$66.46 P/Share
|
|
Jan 25
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 25
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,000
-53.1%
|
$3,300,000
$66.37 P/Share
|
|
Jan 25
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+49.51%
|
$300,000
$6.32 P/Share
|
|
Jan 22
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-68.41%
|
$990,000
$66.71 P/Share
|
|
Jan 22
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|
|
Jan 21
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
23,370
-59.38%
|
$1,542,420
$66.85 P/Share
|
|
Jan 21
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,370
+49.28%
|
$140,220
$6.32 P/Share
|
|
Jan 21
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-80.81%
|
$990,000
$66.88 P/Share
|
|
Jan 21
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.32 P/Share
|